Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 randomized open-label study of radium-223 dichloride versus novel anti-hormonal therapy in bone-metastatic castration-resistant prostate cancer after prior ARPI
MOH_2021-01-03_009624Phase 4Recruiting
- Sponsor
- Bayer
- Start
- Jun 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of radium-223 dichloride, abiraterone and enzalutamide in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Bayer. Started Jun 2020; status: recruiting.
02
Drugs
radium-223 dichlorideabirateroneenzalutamide
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2021-01-03_009624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-03_009624.